Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer

Archives of Andrology

Volumn 53, Issue 2, 2007, Pages 87-90

  Tanaka, N ^b   Fujimoto, K ^b   Hirao, Y ^a   Shimizu, K ^b   Tsujimoto, S ^b   Samma, S ^b  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

Goserelin; Leuprolide; Luteinizing hormone releasing hormone agonist; Prostate cancer; Testosterone

Indexed keywords

GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; GOSERELIN; HUMANS; INJECTIONS, SUBCUTANEOUS; KINETICS; LEUPROLIDE; LUTEINIZING HORMONE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 34247375587     PISSN: 01485016     EISSN: 15210375     Source Type: Journal    
DOI: 10.1080/01485010601166870     Document Type: Article

References (14)

1. Bolla M, Collette L, et al. (2002): Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103-108.
2. Crawford ED, Eisenberger MA, et al. (1989): A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424.
3. Denis LJ, Carneiro de Moura JL, et al. (members of the EORTC GU Group and EORTC Data Center) (1993): Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42:119-130.
4. Fernandez del Moral P, Dijkman GA, et al. (1996): Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch south east cooperative urological group. Urology 48:894-900.
5. Heyns CF, Simonin MP, et al. (2003): Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 92:226-231.
6. Japanese Urological Association and Japanese Society of Pathology (2001): General rules for clinical and pathological studies on prostate cancer. Kanehara, Tokyo, pp 72-89.
7. Kaisary AV, Tyrrell CJ, et al. (1991): Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67:502-508.
8. Kuhn JM, Abourachid H, et al. (1997): A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur Urol 32:397-403.
9. Labrie F, Dupont A, et al. (1984): Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci U S A 81:3861-3863.
10. Labrie F, Dupont A, et al. (1987): Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 138:804-806.
11. Messing EM, Manola J, et al. (1999): Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788.
12. Pilepich MV, Winter K, et al. (2005): Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285-1290.
13. The Leuprolide Study Group (1984): Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281-1286.
14. Vogelzang NJ, Chodak GW, et al. (1995): Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 46:220-226.